Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An update from Diaceutics ( (GB:DXRX) ) is now available.
Diaceutics has inaugurated a new US headquarters in Newport, New Jersey, to bolster its local sales and marketing teams’ efforts and strengthen partnerships with its life science customers in the Northeastern US, which accounts for around 90% of its revenue. This strategic move is part of Diaceutics’ expansion plans, following the recruitment of senior sales personnel in 2024, and aims to enhance the company’s presence and customer engagement in the US market.
More about Diaceutics
Diaceutics is a leading technology and solutions provider to the pharma and biotech industry, offering an end-to-end commercialization solution for precision medicines. The company focuses on data analytics, scientific, and advisory services through its DXRX – The Diagnostics Network® platform, with a mission to ensure every patient receives the right test and therapy for their condition.
YTD Price Performance: 30.21%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $150.1M
Find detailed analytics on DXRX stock on TipRanks’ Stock Analysis page.
